Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033036 (APC)
 10,214 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of this study was to evaluate the shear bond strengths of a composite resin (Transbond XT; 3M/Unitek, Monrovia, Calif) and a resin-modified glass ionomer (Fuji Ortho LC; GC America Inc, Alsip, Ill) cured with 2 different light-curing units: a conventional visible light unit (Ortholux XT; 3M Dental Products, St Paul, Minn) and a xenon arc light unit (Plasma Arc Curing [PAC] System; American Dental Technologies, Corpus Christi, Texas). One hundred twenty freshly extracted bovine permanent mandibular incisors were randomly divided into 1 of 8 groups; each group consisted of 15 specimens. Two groups (1 group for each type of adhesive) were exposed to the visible light for 20 seconds (Transbond XT) and 40 seconds (Fuji Ortho LC), respectively, and used as control groups. The remaining 6 groups (3 for each adhesive) were cured with the xenon arc light for 2, 5, and 10 seconds. After bonding, all samples were stored in distilled water at room temperature for 24 hours and subsequently tested in a shear mode on an Instron universal testing machine (Instron Corp, Canton, Mass). For the groups bonded with Transbond XT, no statistically significant differences (P =.868) were found between the shear bond strength of the control group cured with Ortholux XT and those of the groups cured with the PAC System for 2, 5, or 10 seconds. When the shear bond strengths of the groups bonded with Fuji Ortho LC were evaluated, no statistically significant differences (P =.087) were found between the control group that was cured with Ortholux XT and those cured with the PAC System. The bond strength of the composite resin was significantly higher than that of the resin-modified glass ionomer in all the groups tested (P <.0001). The present findings indicate that, compared with visible light-curing, the xenon arc light enables the clinician to significantly reduce the curing time of both bonding agents, without affecting their shear bond strengths. Therefore, xenon arc light sources can be recommended as an advantageous alternative for curing both composite resins and resin-modified glass ionomers.
 ...
PMID:Effects of conventional and high-intensity light-curing on enamel shear bond strength of composite resin and resin-modified glass-ionomer. 1117 37

Two adhesive systems, Transbond APC II (3M Unitek, Monrovia, Calif) and Quick Cure (Reliance Orthodontic Products, Itasca, Ill), were used to determine the efficacy of precuring the liquid resin primer phase of the systems to increase shear bond strength. One hundred sixty bovine incisors were divided into groups of 20 specimens. In 1 group, the primer was cured before placement of the bracket with the filled adhesive material, and, in the other group, the primer was not precured. The shear-peel bond strength was tested with a testing machine at 30 minutes and 24 hours. No statistically significant difference in bond strength was found between the groups that had or had not been precured. More adhesive remained on the teeth with the Transbond when the primer was not precured. There is no advantage or disadvantage in bracket bond strength by precuring the primer before placing the bracket and filled component of the adhesive.
 ...
PMID:Effect of primer precuring on the shear bond strength of orthodontic brackets. 1559 18

Objective We evaluated the safety and efficacy of vonoprazan-based amoxicillin and clarithromycin 7-day triple therapy (VAC) in comparison to proton pump inhibitor (PPI)-based (PAC) as a first-line treatment and vonoprazan-based amoxicillin and metronidazole 7-day triple therapy (VAM) in comparison to PPI-based (PAM) as a second-line treatment for the eradication of Helicobacter pylori in Japan. Methods We performed a non-randomized, multi-center, parallel-group study to compare first-line VAC to PAC and second-line VAM to PAM. A pre-planned subgroup analysis on CAM resistance was also performed. Safety was evaluated with an adverse effects questionnaire (AEQ), which was completed by patients during therapy. Results The first-line eradication rates (ER) in the intention-to-treat (ITT) and per protocol (PP) analyses were 84.9% (95% CI: 81.9-87.6%, n=623) and 86.4% (83.5-89.1%, n=612), respectively, for VAC and 78.8% (75.3-82.0%, n=608) and 79.4% (76.0-82.6%, n=603), respectively, for PAC. The ER of VAC was higher than that of PAC in the ITT (p=0.0061) and PP analyses (p=0.0013). The ERs for VAC in patients with CAM-resistant and CAM-susceptible bacteria were 73.2% (59.7-84.2%, n=56) and 88.9% (83.4-93.1%, n=180), respectively. PAC was associated with higher AEQ scores for diarrhea, nausea, headache, and general malaise. In the second-line ITT and PP analyses VAM achieved ERs of 80.5% (74.6-85.6%, n=216) and 82.4% (76.6-87.3%, n=211), respectively, while PAM achieved ERs of 81.5% (74.2-87.4%, n=146) and 82.1% (74.8-87.9%, n=145), respectively. No significant differences were observed in the ITT (p=0.89) or PP (p=1.0) analyses. Conclusion The ER of first-line VAC was higher than that of PAC, but still <90%. No difference was observed between second-line VAM and PAM. Vonoprazan-based triple therapy was safe and well tolerated.
 ...
PMID:The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. 2856 87